Business
Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"IRVING, Texas, Dec. 4, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading cancer centers, including those within the Caris Precision Oncology Alliance ™ (Caris POA), will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025.\n \n \n \n \n \n \n \nThe studies investigated seven distinct breast cancer subtypes, including HR+/HER2–, HER2-positive, HER2-low/ultralow/null, triple-negative, invasive lobular carcinoma, male and metastatic. The range of studies demonstrates how multi-omics-driven profiling, subtyping and biomarker discovery accelerate precision oncology and improve patient outcomes. The studies represent 40+ collaborating institutions, including leading NCI-designated cancer centers.\"SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris' multi-omic tumor profiling is helping define molecularly distinct patient groups,\" said George W. Sledge, Jr., MD, Caris EVP and Chief Medical Officer. \"By integrating whole exome and whole transcriptome sequencing with IHC profiling and AI-driven signatures, we are uncovering new insights into therapeutic resistance and real-world outcomes that bring us closer to truly personalized cancer care.\"\"The selection of two studies we collaborated on for oral and rapid oral presentations underscores Caris' leadership in multimodal AI for recurrence prediction and risk stratification in early and late breast cancer,\" said Caris President David Spetzler, MS, PhD, MBA.Oral Presentation:Multimodal Artificial Intelligence (AI) Models Integrating Image, Clinical, and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx. Oral #GS1-09General Session 1. December 10, 2025. 11:30 AM-11:45 AM CSTRapid Oral Presentation:A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+ Early Breast Cancer. Rapid Oral #RF3-07Rapid Fire 3. December 10, 2025. 5:18-5:26 PM CSTSpotlight Posters Include: Personalized Acquired CDK4/6i Resistance: Associations with Baseline Characteristics Like Obesity in Real-...